Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norman Stockbridge

Showing results (21-30 of 143) with videos related to

Pageof 15
Sort By:
Journal of Electrocardiology|September 25, 2012
Practice and challenges of thorough QT studiesNorman Stockbridge, Joanne Zhang, Christine Garnett, et al.
Drug Safety|July 12, 2015
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14Borje Darpo, Christine Garnett, James Keirns, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Lessons Learned From Hundreds of Thorough QT StudiesJoanne Zhang, Huifang Chen, Yi Tsong, et al.
Frontiers in Toxicology|April 9, 2024
Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screeningBrian Berridge, Jennifer Pierson, Syril Pettit, et al.
Circulation|November 9, 2016
Food and Drug Administration Analysis of Ticagrelor: Using Data From an Enriched Trial to Evaluate Benefit-Risk Difference in an Unstudied PopulationTzu-Yun McDowell, Melanie Blank, John Lawrence, et al.
Neoreviews|September 26, 2017
The Role of Biomarkers and Surrogate End Points in Drug Development for Neonatal Pulmonary Arterial HypertensionHaihao Sun, Norman Stockbridge, Ronald L Ariagno, et al.
Drug Safety|February 19, 2013
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Norman Stockbridge, Joel Morganroth, Rashmi R Shah, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Topic of Timely Interest-Decision Criteria for Negative QT Assessment Using Exposure Response Analysis of Data From Early-Phase Clinical Studies: Letter to the EditorBorje Darpo, Georg Ferber, Christine Garnett, et al.
JACC. Heart Failure|December 3, 2016
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure DevicesMatthew Hillebrenner, Bram Zuckerman, Mona Fiuzat, et al.
Therapeutic Innovation & Regulatory Science|September 2, 2020
Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical TrialsYiming Chen, John Lawrence, H M James Hung, et al.
Pageof 15

Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
Journal of Electrocardiology|September 25, 2012
Practice and challenges of thorough QT studiesNorman Stockbridge, Joanne Zhang, Christine Garnett, et al.
Drug Safety|July 12, 2015
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14Borje Darpo, Christine Garnett, James Keirns, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Lessons Learned From Hundreds of Thorough QT StudiesJoanne Zhang, Huifang Chen, Yi Tsong, et al.
Frontiers in Toxicology|April 9, 2024
Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screeningBrian Berridge, Jennifer Pierson, Syril Pettit, et al.
Circulation|November 9, 2016
Food and Drug Administration Analysis of Ticagrelor: Using Data From an Enriched Trial to Evaluate Benefit-Risk Difference in an Unstudied PopulationTzu-Yun McDowell, Melanie Blank, John Lawrence, et al.
Neoreviews|September 26, 2017
The Role of Biomarkers and Surrogate End Points in Drug Development for Neonatal Pulmonary Arterial HypertensionHaihao Sun, Norman Stockbridge, Ronald L Ariagno, et al.
Drug Safety|February 19, 2013
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Norman Stockbridge, Joel Morganroth, Rashmi R Shah, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Topic of Timely Interest-Decision Criteria for Negative QT Assessment Using Exposure Response Analysis of Data From Early-Phase Clinical Studies: Letter to the EditorBorje Darpo, Georg Ferber, Christine Garnett, et al.
JACC. Heart Failure|December 3, 2016
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure DevicesMatthew Hillebrenner, Bram Zuckerman, Mona Fiuzat, et al.
Therapeutic Innovation & Regulatory Science|September 2, 2020
Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical TrialsYiming Chen, John Lawrence, H M James Hung, et al.
Pageof 15